Most Liquid Pharmaceutical Products Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1AAPG Ascentage Pharma Group
1.05 B
 0.06 
 3.19 
 0.18 
2DNLI Denali Therapeutics
1.07 B
(0.12)
 4.56 
(0.56)
3NAGE Niagen Bioscience,
33 M
 0.10 
 7.34 
 0.75 
4MTVA MetaVia
21.62 M
(0.02)
 4.10 
(0.10)
5MRNA Moderna
8.35 B
(0.05)
 5.40 
(0.26)
6MRVI Maravai Lifesciences Holdings
617.45 M
(0.22)
 5.68 
(1.22)
7DVAX Dynavax Technologies
518.17 M
 0.06 
 1.52 
 0.08 
8ME 23Andme Holding Co
410.89 M
(0.23)
 10.10 
(2.27)
9MRUS Merus BV
376.11 M
 0.05 
 2.68 
 0.13 
10DSGN Design Therapeutics
359.38 M
(0.08)
 5.98 
(0.50)
11VALN Valneva SE ADR
336.22 M
 0.18 
 5.30 
 0.98 
12VERV Verve Therapeutics
293.56 M
(0.01)
 5.59 
(0.03)
13MOLN Molecular Partners AG
267.13 M
(0.06)
 4.35 
(0.25)
14FBIOP Fortress Biotech Pref
248.77 M
(0.02)
 2.80 
(0.06)
15MRSN Mersana Therapeutics
225.13 M
(0.18)
 8.67 
(1.55)
16MDGL Madrigal Pharmaceuticals
211.77 M
 0.05 
 4.32 
 0.20 
17MCRB Seres Therapeutics
195.8 M
(0.04)
 5.25 
(0.20)
18DTIL Precision BioSciences
184.14 M
 0.02 
 6.54 
 0.15 
19VKTX Viking Therapeutics
155.02 M
(0.13)
 4.84 
(0.62)
20MNKD MannKind Corp
154.16 M
(0.25)
 1.94 
(0.48)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).